Catalyst Dossier · compiled by CeliA 🧫
Elevance Health, Inc. (ELV)
Hospital & Medical Service Plans · market cap $84.4B · as of 2026-07-08
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-10-20
Earnings
Pipeline
0
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Elevance Health, Inc. (ELV) is a large-cap managed care organization — formerly Anthem, Inc. — serving approximately 46.8 million members across medical, pharmacy, dental, behavioral health, and long-term care plans via Blue Cross Blue Shield affiliates and Carelon. With ~$199B in 2025 revenue and an $88.6B market cap, it is among the largest for-profit health insurers in the U.S. The near-term event is a Q2 2026 earnings report on July 16, rated modest catalyst intensity (5/10).
The catalyst path
- 2026-10-20Earningsimp 5/10
Pipeline
No pipeline data.
Price & technical context
3-month
+3.7%
6-month
+40.4%
12-month
+29.6%
52-wk range
$280.74–$426.79
vs 50-day MA
+3.1%
vs 200-day MA
+12.6%
Realized vol
35.6%
Max drawdown
-51.2%
Daily closes through 2026-09-21. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for ELV (10-K, 10-Q, S-3, 13D/G, Form 4)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.